Nektar Therapeutics (NKTR) dazzled investors in 2025 with its eczema drug rezpegaldesleukin, but its pre-revenue status and binary clinical trial risks make it a speculative bet. Meanwhile, Madrigal Pharmaceuticals (MDGL) is already generating $287M+ in quarterly revenue from its MASH blockbuster Rezdiffra—with a clearer path to long-term growth. For investors seeking biotech exposure without the volatility, the choice is clear.
The 2025 Biotech Rollercoaster: Nektar’s Meteoric Rise and the Reality Check
Nektar Therapeutics became one of 2025’s most talked-about biotech stocks after its experimental eczema drug rezpegaldesleukin delivered phase 2b trial results that sent shares soaring. The data positioned rezpegaldesleukin as a potential competitor to blockbuster immunology drugs like Dupixent (annual sales: $13.6B in 2025) and Rinvoq ($3.2B). For a company with no approved products, this was a rare validation moment.
Yet the celebration obscures a harsh truth: 90% of drugs entering phase 3 trials fail to reach approval. Nektar’s entire valuation now hinges on rezpegaldesleukin’s success in late-stage studies—a binary outcome that could either:
- Triple the stock if trials succeed and the drug gains FDA approval in the $30B+ eczema market
- Collapse shares by 80%+ if trials fail, leaving Nektar with no revenue and dwindling cash reserves
This isn’t hypothetical. In September 2025, aTyr Pharmaceuticals saw its stock evaporate after its lead drug—which had shown mid-stage promise—failed in phase 3. Nektar’s $1.2B market cap today reflects both the opportunity and the abyss.
Madrigal’s Quiet Revolution: From Clinical Hope to Commercial Powerhouse
Madrigal Pharmaceuticals was in Nektar’s shoes just 18 months ago: a pre-revenue biotech with a single high-potential drug. The difference? Madrigal’s Rezdiffra crossed the finish line, becoming the first FDA-approved treatment for MASH (metabolic dysfunction-associated steatohepatitis) in March 2024. The results since then have rewritten the company’s trajectory:
- $287.3M in Q3 2025 revenue—a 47% sequential jump—putting it on track for $1B+ annual sales in 2026
- 90%+ prescription growth in its first year, with 1,200+ physicians now prescribing Rezdiffra
- Peak sales estimates of $5B+ by 2030, targeting a MASH patient population of 6–8 million Americans
Crucially, Rezdiffra operates in a market with zero direct competitors. While Nektar faces entrenched players like Sanofi (Dupixent) and AbbVie (Rinvoq), Madrigal is writing the rules for MASH treatment—a disease with no prior FDA-approved therapies. This first-mover advantage translates to:
- Pricing power: Rezdiffra’s $47,000/year list price faces minimal pushback from payers
- Regulatory goodwill: The FDA’s accelerated approval pathway reflects the urgent unmet need
- Longer patent runway: No biosimilar threats until at least 2038
The Risk/Reward Mismatch: Why Madrigal Wins for Most Investors
Both companies operate in high-potential markets, but their risk profiles diverge dramatically:
| Nektar Therapeutics (NKTR) | Madrigal Pharmaceuticals (MDGL) | |
|---|---|---|
| Revenue | $0 (pre-commercial) | $287.3M Q3 2025 (47% QoQ growth) |
| Lead Drug Status | Phase 3 trials (50% historical failure rate) | FDA-approved (March 2024) with accelerating uptake |
| Market Opportunity | Crowded ($30B eczema market with 5+ competitors) | Monopoly (MASH market with no approved alternatives) |
| Downside Risk | 80%+ stock collapse if trials fail | Limited to macroeconomic/sector risks |
| Upside Potential | 300%+ if approved (but binary outcome) | 150–200% over 3 years with execution |
The data reveals a critical insight: Madrigal offers 70% of Nektar’s upside with 90% less risk. While Nektar’s stock could triple on approval, Madrigal’s revenue growth and market dominance provide a more predictable path to share appreciation. For investors who:
- Can’t afford to lose principal
- Prefer compounding growth over lottery-ticket bets
- Want exposure to biotech’s innovation without the volatility
Madrigal emerges as the superior choice. Even conservative models project its revenue reaching $2.5B by 2027—valuing the company at 4–5x current levels.
The One Scenario Where Nektar Might Be Worth the Gamble
Nektar isn’t without merit for high-risk-tolerance investors. Three factors could justify a speculative position:
- Eczema’s massive market: Even 5% penetration of the $30B market would generate $1.5B in sales—enough to justify the current valuation
- Pipeline optionalities: Nektar has 3 other clinical-stage assets that could create value if rezpegaldesleukin stumbles
- M&A potential: Big Pharma may acquire Nektar for its immunology platform if phase 3 data is positive (precedent: Pfizer’s $11.6B acquisition of Arena Pharmaceuticals in 2021)
However, these catalysts require perfect execution. The company must:
- Deliver flawless phase 3 data (expected H1 2026)
- Secure FDA approval without additional trials
- Compete effectively against entrenched players with superior commercial infrastructure
History suggests only 1 in 10 biotechs navigate this gauntlet successfully. For every Regeneron (which turned early-stage promise into a $90B company), there are dozens of aTyrs that flame out spectacularly.
What Wall Street’s Top Analysts Are Saying
The Street’s consensus reflects this risk/reward divide:
- Nektar Therapeutics:
- 12-month price targets range from $5 (bear case) to $45 (bull case)
- Average target: $22 (38% upside from current $16)
- 50% of analysts rate it “Hold”—a rarity for a clinical-stage biotech
- Madrigal Pharmaceuticals:
- 12-month price targets cluster between $220–$280 (current: $165)
- Average target: $250 (52% upside)
- 80% “Buy” ratings with no “Sell” recommendations
Notably, Bloomberg data shows institutional ownership at 85% for Madrigal versus 62% for Nektar—a telling vote of confidence from professional investors who prioritize risk-adjusted returns.
Actionable Investor Takeaways for 2026
For aggressive investors:
- Consider a small position (≤5% of portfolio) in Nektar, but set a stop-loss at $10 to limit downside
- Watch for phase 3 data in H1 2026—this is the only catalyst that matters
- Be prepared to sell immediately on any negative trial readouts
For growth-oriented investors:
- Madrigal is the clear choice—allocate 3–5% of your biotech exposure here
- Monitor the confirmatory trial results (expected 2027) for Rezdiffra’s long-term viability
- Look for pullbacks below $150 as buying opportunities
For all investors:
- Avoid overconcentration: Biotech should comprise ≤10% of most portfolios
- Diversify across market caps (e.g., pair Madrigal with established players like Amgen or Gilead)
- Watch for MASH market developments—competitors like Akero Therapeutics (phase 3 data due 2026) could impact Madrigal’s monopoly
The Bottom Line: Why Madrigal Is the 2026 Biotech Play
The biotech sector will always offer high-risk, high-reward opportunities like Nektar. But 2026’s macroeconomic environment—with rising interest rates and heightened market volatility—favors companies with visible revenue growth and clear pathways to profitability. Madrigal Pharmaceuticals checks these boxes while offering exposure to one of medicine’s most underserved markets.
Nektar’s story is compelling, but it remains just that—a story until rezpegaldesleukin proves itself in phase 3. Madrigal has already crossed that chasm. For investors who want innovation without the existential risk, the choice is clear.
Stay ahead of the market’s biggest moves with onlytrustedinfo.com‘s real-time analysis. We cut through the noise to deliver the fastest, most authoritative insights—so you can invest with confidence in 2026’s most transformative opportunities.
